Progress, Potential, and Possibilities Podcast / Show · 2026-06-02 · 31 min
Send us Fan Mail For years, T cell therapies have transformed blood cancers - but solid tumors have remained one of the hardest problems in medicine. Now a new company called Deck Bio believes the issue isn’t just finding a better target...it’s that cancer may never have been a single-target disease in the first place. Dr. Jack Silberstein, Ph.D. is the Founder and CEO of Deck Bio ( ), a biotechnology company developing next-generation T cell engager therapies designed to address one of the most persistent challenges in solid tumor immunotherapy: antigen heterogeneity and immune escape. Deck Bio’s platform takes a multi-target approach, engineering T cell receptors to simultaneously recognize multiple peptide-MHC (pMHC) complexes, with the goal of improving both tumor specificity and durable anti-tumor activity while reducing the on-target/off-tumor toxicity that has limited earlier T cell engager strategies. Prior to founding Deck Bio, Dr. Silberstein trained as an immunology Ph.D.
Other episodes covering the same guests and topics, from across The B2B Podcast Index.
The Scientist Turned VC Funding the Cure for Aging with Omri Amirav-DroryVentures from The Valley · on Biotech81 / 100
The Frontier State of Nonprofit AcceleratorsThe Frontier State Podcast · on Biotech78 / 100
Putting the “Tech” in Biotech: An Unconventional Path to Building a Therapeutics Company, with Federico Paoletti, PhDBuilding Biotechs · on Immunotherapy72 / 100
Deep Tech Gold Rush: Smart Boom or Future Bust?Venture Unlocked · on Biotech71 / 100
#139 Justin Coombs, COO at AusHealth on Revolutionising Healthcare Through InnovationCreating Synergy Podcast · on Immunotherapy71 / 100
This Just In Radio: CancerX 2026 with Dr. John Cleveland and Xavier AvatThis Just In Radio Show · on Immunotherapy68 / 100Building the Internet of Medicine: How AI Could Transform Children's Healthcare | Dr. Timothy Chou - Founder, Pediatric Moonshot92 / 100The Blood Test That Could Change Cancer Treatment Forever | Eric Matthews - General Manager, Biopharma, Natera65 / 100How Female Biology Shapes Skin Disease Across a Lifetime | Dr. Doral Fredericks, PharmD, MBA - Vice President and Head of Global Medical Affairs and Outcomes Research, Organon56 / 10055 Years Without a Diagnosis | Can AI Solve The Undiagnosed Condition Blind Spot? | Haresh Patel - Founder and CEO, Sanare Health AI70 / 100How Regenerative Medicine Is Reinventing Breast Reconstruction | Dr. Claudia Chavez-Munoz, MD, PhD - Chief Scientific Officer and Co-Founder - Conexeu Sciences